Seattle Genetics Phase II NSCLC results

(SGEN) said in a U.S. Phase II trial in 62 patients with non-small cell lung cancer (NSCLC), patients receiving SGN-15 plus Taxotere docetaxel had a median overall survival of 7.3 months compared to 5.9 months for patients receiving Taxotere alone. Interim results released in August 2003 showed the combination therapy had a median survival of 11.4 months versus 5.1 months for patients receiving only Taxotere. Patients in the trial had failed at least 1 prior therapy. The primary endpoint of the trial was overall survival. Predicted overall survival at one year and 18 months for patients given the combination treatment was 29% and 18%, respectively, compared to 24% and 8% for patients on chemotherapy alone. ...